> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hospira Recalls 1 Propofol Lot
- URL: https://www.fdaweb.com/hospira-recalls-1-propofol-lot/
- Published: 2022-07-14T12:00:00.000Z
- Updated: 2026-09-14T17:52:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152271

Pfizer’s Hospira unit is recalling one lot of propofol injectable emulsion (containing benzyl alcohol) due to a visible particulate observed in a single vial during annual examination of retained samples. An FDA [notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-issues-voluntary-nationwide-recall-one-lot-propofol-injectable-emulsion-usp-containing?utm%5Fmedium=email&utm%5Fsource=govdelivery#recall-announcement) says patients receiving the affected product are at risk of experiencing life-threatening adverse clinical effects including blockage of blood vessels and decreased blood to the brain; heart attack; pulmonary embolus; and tissue necrosis. The notice says that to date Hospira has not received reports of any adverse events associated with this issue for this lot.